Table 5.
Changes of day arterial stiffness parameters after 3 mo omega-3 polyunsaturated fatty acid therapy
|
Patients with T2DM and CAN (n = 39) |
||||
| Groups | Baseline | After treatment | % change from baseline | |
| AIxao (%) | Control group | 30.4 ± 1.97 | 28.4 ± 1.68 | -4.3% ± 4.76% |
| Treatment group | 32.0 ± 1.32 | 26. 4 ± 1.12b | -16.2% ± 3.12% | |
| AIxbr (%) | Control group | -10.6 ± 3.37 | -12.0 ± 3.11 | -19.3% ± 12.14% |
| Treatment group | -9.8 ± 2.76 | -14.3 ± 2.84 | -42.8% ± 9.0% | |
| PWV (m/s) | Control group | 10.2 ± 0.4 | 9.6 ± 0.4 | -6.0% ± 2.21% |
| Treatment group | 11.0 ± 0.35 | 9.7 ± 0.39a | -11.6% ± 2.09% | |
The results are given as absolute values and as % change from baseline, (Δ%, Mean ± SEM);
a
P < 0.05,
b
P < 0.01, - compared to baseline. T2DM: Type 2 diabetes mellitus; CAN: Cardiac autonomic neuropathy; AIxao: Aortha augmentation index; AIxbr: Brachial augmentation index; PWV: Pulse wave velocity.